Chengdu Kanghong Pharmaceuticals Group Co Ltd - Asset Resilience Ratio
Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has an Asset Resilience Ratio of 4.31% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2022)
This chart shows how Chengdu Kanghong Pharmaceuticals Group Co Ltd's Asset Resilience Ratio has changed over time. Check Chengdu Kanghong Pharmaceuticals Group C (002773) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Chengdu Kanghong Pharmaceuticals Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Chengdu Kanghong Pharmaceuticals Group C.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥440.00 Million | 4.31% |
| Total Liquid Assets | CN¥440.00 Million | 4.31% |
Asset Resilience Insights
- Limited Liquidity: Chengdu Kanghong Pharmaceuticals Group Co Ltd maintains only 4.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Chengdu Kanghong Pharmaceuticals Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621 |
Drug Manufacturers - Specialty & Generic | 2.04% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
|
Jw Pharmac
KO:001060 |
Drug Manufacturers - Specialty & Generic | 3.65% |
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Samjin Pharm
KO:005500 |
Drug Manufacturers - Specialty & Generic | 0.25% |
Annual Asset Resilience Ratio for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2015–2022)
The table below shows the annual Asset Resilience Ratio data for Chengdu Kanghong Pharmaceuticals Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 1.30% | CN¥100.00 Million ≈ $14.63 Million |
CN¥7.72 Billion ≈ $1.13 Billion |
-1.58pp |
| 2021-12-31 | 2.88% | CN¥200.00 Million ≈ $29.27 Million |
CN¥6.96 Billion ≈ $1.02 Billion |
-1.21pp |
| 2018-12-31 | 4.08% | CN¥212.00 Million ≈ $31.02 Million |
CN¥5.19 Billion ≈ $760.17 Million |
-2.84pp |
| 2016-12-31 | 6.92% | CN¥260.00 Million ≈ $38.05 Million |
CN¥3.76 Billion ≈ $549.94 Million |
-0.32pp |
| 2015-12-31 | 7.24% | CN¥210.00 Million ≈ $30.73 Million |
CN¥2.90 Billion ≈ $424.54 Million |
-- |
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices in China. It develops medicines for ophthalmic, neuropsychiatric, and others. The company was founded in 1996 and is headquartered in Chengdu, China.